[LCID Study Number: 20203128]

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

The purpose of this study is to compare the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non small cell lung cancer that has been removed by surgery.

Disease/Condition: Non-Small Cell Lung Cancer

Department: Hematology and Oncology

Status: Active, Not Recruiting

Location(s): Addison Gilbert Hospital; Beverly Hospital; Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421